FDA-cleared profile

Transpara

ScreenPoint Medical BV · Mammography/DBT · FDA-cleared (510(k))

Authorized purpose: Transpara is a concurrent reading aid for screening mammograms that marks suspicious regions, lesions, and calcifications and provides malignancy scores for qualified physician review; patient management is not based solely on the device.

Clinical role
Screening mammography review or breast-density analysis as an adjunct to qualified physician interpretation.
Images and patients
Mammography/DBT · Breast
Key limitation
Keep in mind: Compatible acquisition system, image quality, breast view, population, display, and physician-review requirements are release-specific. Transpara is a concurrent reading aid for screening mammograms that marks suspicious regions, lesions, and calcifications and provides malignancy scores for qualified physician review; patient management is not based solely on the device.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: Transpara is a concurrent reading aid for screening mammograms that marks suspicious regions, lesions, and calcifications and provides malignancy scores for qualified physician review; patient management is not based solely on the device.
  • Which images or clinical context are in scope?Modality: Mammography/DBT Anatomy or clinical context: Breast Input: Supported digital mammography or breast-tomosynthesis image data from compatible systems.
  • Who uses it?Intended users: Qualified mammography technologists and interpreting physicians.
  • What does the software produce?Output: Suspicious-region markings, scores, density measurements, density categories, or other release-specific breast-imaging outputs.
  • What is its most important limitation?Key limitation: Compatible acquisition system, image quality, breast view, population, display, and physician-review requirements are release-specific. Transpara is a concurrent reading aid for screening mammograms that marks suspicious regions, lesions, and calcifications and provides malignancy scores for qualified physician review; patient management is not based solely on the device.

Clinical takeaway. Clinical role: Transpara is a concurrent reading aid for screening mammograms that marks suspicious regions, lesions, and calcifications and provides malignancy scores for qualified physician review; patient management is not based solely on the device.

Evidence takeaway. Evidence from the reviewed source record: The exact FDA document reports standalone testing of the CADe marks on a multi-vendor mammography test set from multiple centers: sensitivity 94.1 (95% CI 90.6-97.1) for malignant calcification groups at 0.23 false-positive marks per image, and 72.0 (95% CI 67.4-76.5) for soft tissue lesions at 0.033 per image. A fully-crossed retrospective MRMC reader study (fourteen radiologists, 240 cases) found average reader AUC increased from 0.866 to 0.886 (+0.020, 95% CI = 0.010 – 0.030). Results are as reported in the FDA submission, not independent validation.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
Transpara is a concurrent reading aid for screening mammograms that marks suspicious regions, lesions, and calcifications and provides malignancy scores for qualified physician review; patient management is not based solely on the device.
  • Exact FDA submission
  • Checked 2026-09-04
Workflow role
Screening mammography review or breast-density analysis as an adjunct to qualified physician interpretation.
  • Exact FDA submission
  • Checked 2026-09-04
Required input
Supported digital mammography or breast-tomosynthesis image data from compatible systems.
  • Exact FDA submission
  • Checked 2026-09-04
Output and clinician action
Suspicious-region markings, scores, density measurements, density categories, or other release-specific breast-imaging outputs.
  • Exact FDA submission
  • Checked 2026-09-04
Care setting
Breast-imaging practices using compatible digital mammography or tomosynthesis systems.
  • Exact FDA submission
  • Checked 2026-09-04
Intended users
Qualified mammography technologists and interpreting physicians.
  • Exact FDA submission
  • Checked 2026-09-04
Limitations
Compatible acquisition system, image quality, breast view, population, display, and physician-review requirements are release-specific. Transpara is a concurrent reading aid for screening mammograms that marks suspicious regions, lesions, and calcifications and provides malignancy scores for qualified physician review; patient management is not based solely on the device.
  • Exact FDA submission
  • Checked 2026-09-04
Evidence summary
The exact FDA document reports standalone testing of the CADe marks on a multi-vendor mammography test set from multiple centers: sensitivity 94.1 (95% CI 90.6-97.1) for malignant calcification groups at 0.23 false-positive marks per image, and 72.0 (95% CI 67.4-76.5) for soft tissue lesions at 0.033 per image. A fully-crossed retrospective MRMC reader study (fourteen radiologists, 240 cases) found average reader AUC increased from 0.866 to 0.886 (+0.020, 95% CI = 0.010 – 0.030). Results are as reported in the FDA submission, not independent validation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Validation testing consisted of determining stand-alone performance of the algorithms in Transpara™ using a multi-vendor testset of mammograms acquired from multiple centers" … "Sensitivity and specificity of the CADe marks for detection of malignant calcification groups and soft tissue lesions were determined with 95% confidence intervals obtained by bootstrapping. Sensitivity for calcifications was 94.1 (90.6-97.1) with a false positive rate of 0.23 (0.22-0.25) marks per image.". Read from the exact FDA decision document on 2026-11-14.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The exact FDA document reports standalone testing of the CADe marks on a multi-vendor mammography test set from multiple centers: sensitivity 94.1 (95% CI 90.6-97.1) for malignant calcification groups at 0.23 false-positive marks per image, and 72.0 (95% CI 67.4-76.5) for soft tissue lesions at 0.033 per image. A fully-crossed retrospective MRMC reader study (fourteen radiologists, 240 cases) found average reader AUC increased from 0.866 to 0.886 (+0.020, 95% CI = 0.010 – 0.030). Results are as reported in the FDA submission, not independent validation.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Validation testing consisted of determining stand-alone performance of the algorithms in Transpara™ using a multi-vendor testset of mammograms acquired from multiple centers" … "Sensitivity and specificity of the CADe marks for detection of malignant calcification groups and soft tissue lesions were determined with 95% confidence intervals obtained by bootstrapping. Sensitivity for calcifications was 94.1 (90.6-97.1) with a false positive rate of 0.23 (0.22-0.25) marks per image.". Read from the exact FDA decision document on 2026-11-14.

Reported sensitivity
Standalone sensitivity of CADe marks for detecting malignant calcification groups on a multi-vendor, multi-center test set: 94.1 (95% CI 90.6-97.1) at 0.23 false-positive marks per image; for soft tissue lesions: 72.0 (95% CI 67.4-76.5) at 0.033 per image.
  • FDA source
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Validation testing consisted of determining stand-alone performance of the algorithms in Transpara™ using a multi-vendor testset of mammograms acquired from multiple centers" … "Sensitivity and specificity of the CADe marks for detection of malignant calcification groups and soft tissue lesions were determined with 95% confidence intervals obtained by bootstrapping. Sensitivity for calcifications was 94.1 (90.6-97.1) with a false positive rate of 0.23 (0.22-0.25) marks per image.". Read from the exact FDA decision document on 2026-11-14; this is the submission-reported standalone result, not independent validation.

Reported specificity
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No exact submission and version-linked specificity endpoint is published in this dossier; do not substitute a product-family or candidate-study value.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

FDA submission-specific verification and validation evidence for K181704

  • DesignRegulatory verification, validation, and labeling evidence reviewed for exact FDA submission K181704.
  • PopulationThe labeled population and test materials for exact submission K181704; a general clinical study population is not established here.
  • Scopeexact submission
  • Tested versionTranspara (K181704)
  • IndependenceSponsor or vendor study

K181704

FDA regulatory evidence is submission-specific but is not independent clinical performance evidence.

5 unlinked candidate evidence records are retained for source review and excluded from this evidence display.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Not established in reviewed sources
  • Reviewed sources checked
  • Exact FDA submission
  • Checked 2026-09-04

No native submission-identifier match was found in the checked openFDA radiology recall snapshot. Product-name, manufacturer, and adverse-event searches remain necessary; this does not establish that no recall or safety report exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Supported digital mammography or breast-tomosynthesis image data from compatible systems.

    Scope: Exact FDA submission.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-04 · FDA decision summary for K181704 - Transpara

  2. Routing

    Source context, not route validation: The exact FDA package describes Transpara configured as a DICOM node that receives input images from another DICOM node, such as a mammography device or PACS archive, and can transmit results to workstations or archives using the DICOM mammography CAD SR protocol. Interface versions and local compatibility require confirmation.

    Scope: Exact FDA submission. Packet wording: "Transpara™ is configured as a DICOM node in a network and receives its input images from another DICOM node, such as a mammography device or a PACS archive." … "Processing results of Transpara™ can be transmitted to external destinations, such as medical imaging workstations or archives, using the DICOM mammography CAD SR protocol.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-11-14 · FDA decision summary for K181704 - Transpara

  3. AI processing

    Source context, not route validation: The exact FDA package describes Transpara as consisting of a processing server and an optional viewer. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "The product consists of a processing server and an optional viewer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · FDA decision summary for K181704 - Transpara

  4. Returned objects

    Source context, not route validation: Suspicious-region markings, scores, density measurements, density categories, or other release-specific breast-imaging outputs.

    Scope: Exact FDA submission.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-04 · FDA decision summary for K181704 - Transpara

  5. Viewer/worklist/report

    Unresolved route: Suspicious-region markings, scores, density measurements, density categories, or other release-specific breast-imaging outputs.

    Scope: Exact FDA submission.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-04 · FDA decision summary for K181704 - Transpara

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes Transpara as consisting of a processing server and an optional viewer. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "The product consists of a processing server and an optional viewer.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The exact FDA package describes Transpara configured as a DICOM node that receives input images from another DICOM node, such as a mammography device or PACS archive, and can transmit results to workstations or archives using the DICOM mammography CAD SR protocol. Interface versions and local compatibility require confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "Transpara™ is configured as a DICOM node in a network and receives its input images from another DICOM node, such as a mammography device or a PACS archive." … "Processing results of Transpara™ can be transmitted to external destinations, such as medical imaging workstations or archives, using the DICOM mammography CAD SR protocol.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Security
ScreenPoint Medical's security reporting page states its security program is aligned with ISO/IEC 27001 and describes a vulnerability reporting channel for Transpara. It states alignment, not certification; no controls are listed. Vendor-wide.
  • Vendor-wide
  • Checked 2026-10-25

Vendor statement, not an attestation; exact-release scope is not established.

Training
The 510(k) summary states the intended users of Transpara are physicians qualified to read screening mammograms.
  • Exact FDA submission
  • Checked 2026-10-27

User qualification wording only; the summary specifies no training program or training offering for this device.

Workflow role

Screening mammography review or breast-density analysis as an adjunct to qualified physician interpretation.

exact submission · checked 2026-09-04

This is a submission-anchored intended-use summary, not a local acceptance result.

Input

Supported digital mammography or breast-tomosynthesis image data from compatible systems.

exact submission · checked 2026-09-04

Exact supported inputs and protocol limits must be confirmed from the complete labeling.

Output

Suspicious-region markings, scores, density measurements, density categories, or other release-specific breast-imaging outputs.

exact submission · checked 2026-09-04

Output review, editing, and downstream use remain release- and site-specific.

Vendor family context

Current vendor material is product-family context for K181704 only; exact release, enabled options, deployment, and local interoperability require confirmation.

product family · checked 2026-09-04

Vendor material is not exact-release evidence unless that linkage is separately proven.

Site validation status

Exact local interfaces, deployment topology, security controls, downtime behavior, and support obligations remain unestablished.

exact submission · checked 2026-09-04

Obtain organization-specific implementation evidence before procurement or clinical use.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K181704
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
Mammography/DBT
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Anatomy
Breast
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-04
Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2018-11-21
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
15Source classes checked
18Screened PubMed leads
6Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 18 PubMed and 6 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 18 PubMed and 6 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, vendor documentation, vendor product page, implementation documentation, reimbursement policy, peer reviewed literature, clinical trial registry, fda device recall, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-04 - Exact FDA submission

    No public exact-release price, license fee, subscription, contract, or implementation cost was established in this review.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not applicable - checked 2026-09-04 - Not applicable

    CMS index context was checked, but no product-specific coverage or reimbursement determination is inferred.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed
  • Monitoring: Not verified - checked 2026-10-27 - Exact FDA submission

    Current drift, quality, uptime, alert, escalation, and incident-response commitments for the exact configuration require vendor confirmation.

14 sources - 3 history items

Source ledger

  1. FDA decision summary for K181704 - Transpara

    U.S. Food and Drug Administration - Published 2018-11-21 - Accessed 2026-09-04

    Scope: regulatoryIdentity, productIdentity, indication, modality, anatomy, workflowRole, input, output, limitations, evidenceSummary

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. Transpara model card (K181704)

    American College of Radiology - Published 2026-06-26 - Accessed 2026-09-01

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  7. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  8. ScreenPoint Transpara family context

    ScreenPoint Medical - Accessed 2026-09-04

    Scope: productFamilyContext, workflowRole, implementationCapabilities

  9. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study.

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  10. Screening performance and characteristics of breast cancer detected in the Mammography Screening with Artificial Intelligence trial (MASAI): a randomised, controlled, parallel-group, non-inferiority, single-blinded, screening accuracy study.

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  11. Performance of an Artificial Intelligence Support System on Screening Mammography Cases Proceeding to Stereotactic Biopsy.

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  12. Wide-Angle Tomosynthesis and AI in Diagnostic Mammography

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  13. Artificial Intelligence in Breast Cancer Screening in Region Östergötland Linkoping

    U.S. National Library of Medicine - Accessed 2026-09-04

    Scope: evidenceStudies, productFamilyContext, evidenceDiscovery

  14. ScreenPoint Medical Security Reporting

    ScreenPoint Medical - Accessed 2026-10-25

    Scope: security

Research history

  1. K181704 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K260714

MammoScreen® (5)

Therapixel

Authorized purpose: Flags calcifications, masses, asymmetries and architectural distortions on compatible FFDM or DBT screening examinations; management must not be based solely on MammoScreen output.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-26
FDA-cleared K253825

Saige-Dx

DeepHealth, Inc.

Authorized purpose: Concurrent detection and characterization support for screening DBT mammography

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-06-15
FDA-cleared K252954

MammoSightAI

Neurocareai, Inc. (Dba Savelife.Ai)

Authorized purpose: Tags screening cases as suspicious or blank to aid worklist prioritization; radiologists must review every examination and it does not mark original images.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-05-04
FDA-cleared K260320

Lunit INSIGHT MMG (v1.1.10)

Lunit, Inc.

Authorized purpose: Lunit INSIGHT MMG v1.1.10 aids physicians in detection, localization and characterization of suspicious breast-cancer areas on female screening mammograms from compatible FFDM systems, viewed after the physician's initial read as an adjunct to complete clinical interpretation.

Modality
Mammography/DBT
Anatomy
Breast
Decision
2026-04-23

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history